These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15150671)

  • 1. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
    Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
    Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
    Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
    Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
    Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
    Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
    Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
    Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
    Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
    Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
    Meany HJ; Fox E; McCully C; Tucker C; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
    McGovren JP; Stewart JC; Elfring GL; Smith RB; Soares N; Wood JH; Poplack DG; Von Hoff DD
    Cancer Treat Rep; 1982 Jun; 66(6):1333-41. PubMed ID: 7083237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.